Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060579 · ClinicalTrials.gov registry record · Phase 2
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT01060579: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT01060579 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 217 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01060579, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be different from that of an active control.
Interventions
- DRUG Latanoprost ophthalmic solution
- DRUG AR-12286 0.5% ophthalmic solution
- DRUG AR-12286 0.25% Ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT01060579 record still lists
NCT01060579 is an interventional study that assigns participants to a tested intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 3 interventions - of which Latanoprost ophthalmic solution is the first listed.
NCT01060579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01060579 about?
NCT01060579 is a clinical study titled "Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure". A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be different from that of an active c...
What is the current status of trial NCT01060579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2010-02. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01060579?
The interventions under investigation include: Latanoprost ophthalmic solution (DRUG), AR-12286 0.5% ophthalmic solution (DRUG), AR-12286 0.25% Ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01060579?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01060579's enrollment target sits among peer trials
217 286th of 2000 higher than 1,715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia